India Intensifies Measures to Curb Counterfeit Medicines

The Central Drugs Standard Control Organization (CDSCO) and the Ministry of Health and Family Welfare have implemented a series of regulatory measures to enhance drug quality and mitigate counterfeit medicines. Since December 2022, over 960 drug manufacturing units have undergone risk-based inspections, resulting in more than 860 regulatory actions for non-compliance. Regulatory updates include revised Good Manufacturing Practices norms, digital tracking systems, and the launch of the SUGAM labs portal to digitize drug testing workflows. Furthermore, the government has introduced barcoding and QR coding mandates for drug formulations and bulk drugs to facilitate track and trace capabilities.

Source: Original Link